3 月 14 日，摩根士丹利将 Alpine Immune Sciences 的目标股价提高至 47 美元。 Morgan Stanley raises Alpine Immune Sciences' price target to $47 on March 14.
3 月 14 日，摩根士丹利将 Alpine Immune Sciences (ALPN) 的目标股价从 30 美元上调至 47 美元。 Morgan Stanley raised its price target for Alpine Immune Sciences (ALPN) from $30 to $47 on March 14. 该券商维持该生物技术公司股票的“增持”评级。 The brokerage maintains an "overweight" rating on the biotech company's stock. 其他几位分析师也给予了积极评级，包括奥本海默的“跑赢大盘”评级和HC Wainwright的“买入”评级。 Several other analysts have also given positive ratings, including Oppenheimer's "outperform" rating and HC Wainwright's "buy" rating. Alpine Immune Sciences 报告第四季度收益好于预期，GAAP 每股收益为 0.15 美元，营收为 3085 万美元。 Alpine Immune Sciences reported better-than-expected Q4 earnings, with GAAP earnings of $0.15 per share and revenues of $30.85 million.